Search

A new study led by MSK investigators reveals how some cancer cells become resistant to targeted treatment and suggests what might be done to stop that from happening.

… Thursday, April 9, 2015 Summary Most cancers treated with targeted therapy ultimately become resistant to treatment, stop shrinking, and eventually progress. New research led by investigators at Memorial Sloan Kettering shows how melanoma and lung cancer cells that initially respond to targeted therapies

Chemotherapy is among the most commonly prescribed, and commonly misunderstood, cancer treatments. It’s time to revise what you thought you knew.

… Tuesday, August 30, 2016 Summary Chemotherapy drugs have evolved considerably over the years. Now, we can treat patients with little to no interference in their everyday lives. We have made great strides in treating cancer with chemotherapy drugs, yet myths about these medications still remain. Donna

Discover how cyclist Stacia Smart turned her grief into purpose after her boyfriend died of a brain tumor.

… Friday, January 1, 2021 Bright, athletic, gregarious, and kind, Owen Strong was enjoying a quintessential life in Manhattan. Living with college friends from Tufts, he was working in the family real estate business and recording songs with his band, the Evening Fools. Then, in February 2018, at age 28

It’s not every day that scientists discover a new part of the cell. Two biologists from the Sloan Kettering Institute just did.

… Thursday, November 15, 2018 Summary Scientists at the Sloan Kettering Institute have discovered a new organelle. The finding challenges longstanding ideas about cell structure. Many people probably remember cell organelles from high school biology. Mitochondria are a cell’s “energy factories.” The nucleus

… Thursday, March 12, 2009 Student Research Eric Alonzo Eric Alonzo Recent publications from our students. Eric Alonzo Kovalovsky D, Uche OU, Eladad S, Hobbs RM, Yi W, Alonzo E, Chua K, Eidson M, Kim HJ, Im JS, Pandolfi PP, Sant’Angelo DB. The BTB-zinc finger transcriptional regulator PLZF controls the

MSK researchers shared their latest research developments at the 2021 meeting of the American Association for Cancer Research.

… Wednesday, April 14, 2021 Three Memorial Sloan Kettering experts shared important research findings in plenary talks during Week 1 of the American Association for Cancer Research’s (AACR) virtual Annual Meeting 2021, held from April 10 to 15. Two presentations shed light on how genetic mutations lead

The Prospective Registry Of Multi-Plex Testing (PROMPT) - a new online, volunteer registry for individuals who have been tested for inherited mutations in cancer-causing genes - will provide data vital to improving our understanding of newly discovered, cancer-associated genes and allow current and future generations to better interpret and benefit from knowledge of their genomes.

… Tuesday, September 23, 2014 A newly formed consortium including experts from academic medical centers and commercial genetics laboratories across the country has established the Prospective Registry Of Multi-Plex Testing (PROMPT), an online registry for individuals and families who have undergone testing

Learn how MSK is joining forces with the City of New York to expand access to the COVID-19 vaccine.

… Friday, April 9, 2021 Christy Manso/staff, MSK Staff/vaccinators, Christy in the center Memorial Sloan Kettering Community Programs manager Christy Manso addresses MSK vaccinators. Anika Navaroli/non-staff Resident Anika Navaroli snaps a selfie when it’s her turn to get the vaccine. Claudia Derico/staff

Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD, Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical genomic sequencing by MSK-IMPACT™, a powerful diagnostic test developed at MSK to provide detailed genetic information about a patient’s cancer.

… Monday, May 8, 2017 Memorial Sloan Kettering (MSK) has reached a major milestone in bringing personalized treatments to more cancer patients. Michael Berger, PhD , Ahmet Zehir, PhD, and colleagues have reported an in-depth analysis of the first 10,336 patients whose tumors were submitted for clinical

Chemotherapy after immune checkpoint inhibitors (ICIs) may improve survival rates in patients with heavily pretreated, recurrent ovarian cancer.

… Thursday, September 19, 2019 Chemotherapy after immune checkpoint inhibitors (ICIs) may improve survival rates in patients with heavily pretreated, recurrent ovarian cancer, according to our retrospective review of outcomes for 79 women treated at Memorial Sloan Kettering Cancer Center. Median overall